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AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor
cells and is required for Epo regulation of erythroid-cell differentiation
Saghi Ghaffari, Claire Kitidis, Wei Zhao, Dragan Marinkovic, Mark D. Fleming, Biao Luo, Joseph Marszalek, and Harvey F. Lodish
AKT serine threonine kinase of the protein
kinase B (PKB) family plays essential roles
in cell survival, growth, metabolism, and
differentiation. In the erythroid system, AKT
is known to be rapidly phosphorylated and
activated in response to erythropoietin (Epo)
engagement of Epo receptor (EpoR) and to
sustain survival signals in cultured ery-
throid cells. Here we demonstrate that acti-
vated AKT complements EpoR signaling
and supports erythroid-cell differentiation in
wild-type and JAK2-deficient fetal liver cells.
We show that erythroid maturation of AKT-
transduced cells is not solely dependent on
AKT-induced cell survival or proliferation
signals, suggesting that AKT transduces
also a differentiation-specific signal down-
stream of EpoR in erythroid cells. Down-
regulation of expression of AKT kinase by
RNA interference, or AKT activity by expres-
sion of dominant negative forms, inhibits
significantly fetal liver–derived erythroid-
cell colony formation and gene expression,
demonstrating that AKT is required for Epo
regulation of erythroid-cell maturation.
(Blood. 2006;107:1888-1891)
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Introduction
Protein kinase B (PKB) or AKT is phosphorylated and activated in
response to the erythropoietin (Epo) engagement of its receptor,
downstream of the PI3 kinase. In addition to the regulation of
survival, AKT is involved in many fundamental biologic processes,
including the regulation of cell cycle, differentiation, and interme-
diary metabolism, and is often activated in human cancers.1-3
Activation of the PI3 kinase signaling pathway,4-12 alone in the
absence of other signaling pathways, may be required and suffi-
cient, under certain conditions, to sustain erythroid-cell develop-
ment.4,13,14 In addition, the PI3 kinase signaling pathway, and AKT
specifically, are associated with the pathogenesis of polycythemia
vera in which they may play a role.15-17
Here the potential role of AKT kinase in Epo-induced matura-
tion of primary fetal liver erythroid progenitor cells using an in
vitro system we previously established14 was investigated.
Study design
Cells, flow cytometry, and erythroid colony assay
Isolation of E12.5 JAK2/ and E14 wild-type fetal liver cells, fluorescence-
activated cell sorting (FACS) of TER 119 (glycophorin A–negative)
cells18 enriched for hematopoietic progenitors, and erythroid colony-
forming unit (CFU-E) assay were previously described.14,19
Retroviral transduction
TER 119 wild-type (E14) and JAK2/ (E12.5) fetal liver cells (2  105/
mL) were resuspended in viral supernatants and plated on 60 mm
RetroNectin– (chimeric fibronectin peptide; Takara Biomedicals, Osaka,
Japan) coated dishes as previously described14,19 in the presence of 100
ng/mL each of interleukin-6 (IL-6) and Steel factor (SF) (PeproTech, Rocky
Hill, NJ). GFP-positive cells were FACS sorted the next day and cultured
under the same conditions with or without Epo (2 U/mL) for another
24 hours.
RNA interference
Duplices of oligonucleotides were cloned into BglII/HindIII sites of
MSCV-U3-H1 plasmid and subcloned subsequently into NotI/ScaI sites of
pMSCV-puromycin-IRES-EGFP-U3-H1 plasmid (provided by B.L.).
Real-time PCR analysis
Real-time polymerase chain reaction (PCR) was performed in duplicates on
LightCycler 2.0 (Roche, Indianapolis, IN) using SYBR Green Taq Ready-
Mix (Sigma, St Louis, MO) (as described by Ghaffari et al20). Gene-specific
primers were designed to span intron-exon boundary by Primer Express 2.0
(ABI; Applied Biosystems, Foster City, CA). Relative quantification of
gene expression between multiple samples was achieved by normalization
against 2 of endogenous Hprt, -actin, and/or Rpl32 using the LightCycler
Relative Quantification Software (Roche).
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Results and discussion
Activated AKT complements Epo receptor (EpoR)/JAK2
signaling and supports differentiation of wild-type and
JAK2-deficient fetal liver erythroid progenitor cells
JAK2-deficient and TER 119 wild-type fetal liver cells are
deprived of mature erythroid cells. As expected, erythroid
maturation of CFU-E progenitors contained in TER 119
wild-type (Figure 1A) and JAK2/ fetal liver cells (Figure 1C),
as determined by diaminobenzidine staining of hemoglobin,
required Epo and a functional JAK2 tyrosine kinase. Interest-
ingly, overexpression of a constitutively active form of AKT
(AKT*; Flag-tagged myristylated AKT) (Figure 1A,C, lane 4)
but not wild-type AKT (Figure 1A,C, lane 3) overrides the need
for Epo and JAK2. Activation and not merely overexpression of
AKT is thus required for induction of erythroid differentiation
of fetal liver progenitor cells. The size of the clusters and the
degree of hemoglobinization was comparable between AKT*-
and control-transduced cells of either JAK2/ or wild-type
origin. Overexpression of a dominant negative (DN) form of
AKT in erythroid progenitors resulted in a significant decrease
in the number of mature CFU-E–derived colonies in the
presence of Epo (Figure 1A, lane 5) without a major effect on
the total cell numbers, suggesting that the inhibitory effect of
AKT DN is not due to apoptosis. Equal viral titers used in these
experiments generated routinely similar levels of expression of
AKT wild-type and mutants in heterologous cells (Figure 1B).
Activated AKT and Epo induced similar levels of expression of
-globin in differentiating wild-type progenitor cells (Figure
1D). Expression of the -globin gene was up-regulated by
2-fold after 14 hours and increased with time in activated
AKT-transduced progenitor cells in culture (Figure 1E). The
degree of maturation of JAK2/ fetal liver cells transduced
with either an active AKT in the absence of Epo or with JAK2 in
the presence of Epo was comparable as judged by the up-
regulation of TER 119 (glycophorin A),18 a marker of post–
CFU-E erythroid cells (Figure 1F), and by their morphology and
Wright Giemsa staining (Figure 1G). These results demonstrate
that AKT supports Epo-mediated erythroid-cell maturation
without the need for any additional signaling protein that
requires JAK2 for its activation.
AKT induces a signal required for differentiation of erythroid
progenitor cells
To further determine the stage of erythroid differentiation, the
expression of TER 119 and CD71 (transferrin receptor) in trans-
duced cells was analyzed. In the absence of Epo, expression of
activated AKT (Figure 2A, bottom right panel, and Figure 2B, lane
3), in contrast to wild-type AKT (Figure 2A, bottom left panel, and
Figure 2B, lane 2), induced maturation of erythroid cells to the
CD71/low TER 119 stage of differentiation. Overexpression of
Figure 1. AKT complements EpoR signaling in inducing erythroid differentiation in wild-type and JAK2/ fetal liver progenitor cells. TER 119 E14 wild-type (A) or
JAK2/ (C) fetal liver cells were transduced with a bicistronic retroviral vector (MIG) or MIG containing the indicated inserts and cultured in the presence or absence of Epo
(2 U/mL) on RetroNectin. Thirty-six hours later, live GFP-positive cells from wild-type–(A) or JAK2/-transduced cells (C) were assayed for CFU-E–generated colony content
as determined by diaminobenzidine staining of hemoglobin. Graphs are from duplicates of 4 (A) and 3 (C) independent experiments. The average of the absolute number of
CFU-E–derived colonies formed from vector control–transduced cells in the presence of Epo was 3160  64 (n  4) per 105 wild-type TER 119 cells and 1248  263 per 105
JAK2-transduced JAK2/- (n  3) plated cells. (B) Western blot analysis of transduced NIH 3T3 cells with 1:10 dilution of the retroviral supernatant. The upper band in the
activated AKT*-transduced cells corresponds to the Flag-tagged myristylated AKT. (D) Real-time PCR analysis of the -globin gene in live GFP-positive cells from panel A.
Representative graph from duplicate analysis of 2 independent experiments. (E) Real-time PCR analysis of kinetics of up-regulation of -globin gene expression in TER 119
E14 wild-type fetal liver–derived cells transduced with MIG-AKT* (results expressed as relative to time zero are from total cells). (F) JAK2/ fetal liver–transduced cells with
MIG, MIG-JAK2, or with a constitutively active AKT (MIG-AKT*) and cultured in the presence of Epo (MIG-JAK2 cells) or in the absence of Epo (vector control and MIG-AKT*
cells) were analyzed for erythroid-cell differentiation 36 hours later (note TER 119 cells within transduced GFP-positive cells). (G) Representative field of
Wright-Giemsa staining of live GFP-positive transduced JAK2/-derived cells (magnification,  1000). Arrows show (i) polychromatophilic erythroblast and (ii)
polychromatophilic erythroblast and normoblast. Images were obtained using a Nikon Eclipse E600 microscope (Nikon, Garden City, NJ) and a 100 /0.3 numeric
aperture oil immersion lens. Images were captured using an RT Slider SPOT 2.3.1 camera and SPOT Advanced software (both from Diagnostic Instruments, Sterling
Heights, MI).
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active AKT* had some mild inhibitory effect in the later stages of
fetal liver cell maturation (Figure 2A; compare top and bottom
right panels), although the effect did not seem to be statistically
significant in the limit of the number of experiments per-
formed (Figure 2B; compare populations of CD71 TER 119 in
lanes 3 and 4).
We next investigated whether expression of activated AKT
resulted in a survival advantage that facilitated erythroid-cell
maturation. To our surprise, the survival rate of activated AKT-
transduced cells (in the absence of Epo) was significantly lower
(Figure 2C, right plot) than that of control cells cultured in Epo
(Figure 2C, left plot) as measured by annexin V (an early measure
of apoptosis) binding. These results suggest that AKT may not
substitute for the apoptosis-suppressing function of the Epo-STAT5-
Bcl-XL pathway.
The enhanced erythroid maturation of AKT*-transduced cells
was not accompanied by an increase in total cell number. AKT*-
transduced TER 119 WT fetal liver cells cultured in the absence of
Epo were found less in the S phase (S, 38.5%; G0-G1, 46.8%) as
compared with cells cultured in Epo (S, 47.5%; G0-G1, 42%),
suggesting that AKT induction of erythroid differentiation was not
only due to its enhancement of cell-cycle progression. Thus, the
ability of activated AKT to induce fetal liver erythroid-cell
differentiation does not solely stem from its potential to promote
cell survival or proliferation.
AKT involvement was further evaluated by using RNA interfer-
ence to inhibit the expression of AKT during Epo-induced differen-
tiation of primary fetal liver cells. Retrovirally transduced fetal
liver progenitor-derived cells expressing short hairpin RNA
(shRNA) targeting AKT1 and AKT2 exhibited a significant de-
crease in the expression of red cell–specific genes -globin and
Alas2 (Figure 2D, lane 2) as compared with controls. Inhibition of
expression of AKT also induced a significant suppression of the
number but not the size of CFU-E–derived colonies consistent with
an inhibition of erythroid differentiation of fetal liver cells (data not
shown). The presence of inhibitors of caspase 3, a general inhibitor
of apoptosis in cultured fetal liver cells, did not affect these results.
Collectively, these results further confirmed that the effect of AKT
on erythropoiesis is not limited to its regulation of apoptosis.
The combined data from both JAK2/ and wild-type fetal liver
cells demonstrate that AKT mediates a signal downstream of
EpoR,23 distinct from its survival signal, that supports differentia-
tion of fetal liver erythroid progenitor cells. These data are
consistent with an in vivo role for AKT in normal24 and in
polycythemia vera15-17 hematopoiesis.
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